newsfilter
← Latest News
Business Wire·

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

TTRX
  • Turn Therapeutics announced interim analysis findings from its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis based on the first 50 completed subjects.
  • 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity within 4 weeks compared to 65.2% for the vehicle group.
  • 70.4% of GX-03-treated subjects achieved a 75% reduction in severity at Week 4.
  • 44.4% of GX-03-treated subjects achieved a 90% reduction at Week 4 versus 30.4% for the vehicle group.
  • 51.9% of GX-03-treated subjects achieved a 90% reduction at Week 8 versus 34.8% for the vehicle group.
  • The interim review informed refinements to enrollment criteria, endpoint hierarchy, & the overall trial optimization strategy.
  • No treatment-related serious adverse events, tolerability issues, or discontinuations were observed in either group.
  • The trial is utilizing an integrated Stage 1 analysis to evaluate responder dynamics & optimize the second stage while enrollment continues.
  • Turn Therapeutics plans to initiate FDA interactions to discuss regulatory strategy & potential pathways for GX-03 advancement.
  • Detailed findings will be presented at the Jefferies Global Healthcare conference on June 4, 2026.